ARA-290: Dosing Protocols

Research Dosing Disclaimer#

ARA-290 (cibinetide) is an investigational compound that has not been approved for clinical use. The dosing information below is derived from published clinical trial protocols and is provided for educational purposes only.

Clinical Trial Dosing Protocols#

Intravenous Administration#

In the initial sarcoidosis pilot study (Heij et al., 2012), ARA-290 was administered intravenously at 2 mg per dose, three times weekly, for 4 weeks (12 doses total). This route provided rapid systemic delivery and was used in the controlled clinical setting of the trial.

The intravenous route allowed precise dose delivery and was appropriate for the pilot study design. However, the requirement for clinical administration three times weekly limits the practical applicability of this approach for chronic treatment.

Subcutaneous Administration#

Subsequent clinical studies transitioned to subcutaneous self-administration, which is more practical for chronic daily dosing. The standard subcutaneous dose used in clinical trials was 4 mg per day for 28 days.

In the sarcoidosis follow-up study (Dahan et al., 2013), daily subcutaneous ARA-290 for 28 days improved neuropathic symptoms and increased corneal nerve fiber density. The diabetes study (Brines et al., 2015) used the same 4 mg daily subcutaneous protocol with consistent results.

Dose Rationale#

The transition from 2 mg IV three times weekly to 4 mg SC daily reflects the pharmacokinetics of ARA-290. Despite its very short plasma half-life (approximately 2 minutes), the compound triggers sustained intracellular signaling that persists for hours. Daily administration ensures consistent receptor activation and signaling, while the higher dose compensates for the lower bioavailability of subcutaneous compared to intravenous delivery.

Pharmacokinetic Considerations#

ARA-290 has a very short plasma half-life of approximately 2 minutes due to rapid proteolytic degradation. However, this does not limit its therapeutic effect because the compound acts as a triggering ligand rather than a sustained receptor occupant. Once the innate repair receptor is activated, the downstream signaling cascade (JAK2-STAT5, PI3K-Akt) continues for hours, providing sustained biological effects from brief receptor engagement.

This pharmacokinetic-pharmacodynamic disconnect is an important concept for understanding ARA-290 dosing: the dose needs to be sufficient to briefly exceed the receptor affinity threshold (low nanomolar), but does not need to maintain sustained plasma levels.

Administration Technique#

Subcutaneous Injection#

In clinical trials, patients self-administered subcutaneous injections in the abdomen or thigh. The injection technique follows standard subcutaneous administration practices. The small injection volume and mild formulation resulted in minimal injection site reactions in clinical trial participants.

Intravenous Injection#

For intravenous administration in clinical settings, ARA-290 was diluted in sterile saline and administered as a slow injection. This route was used only in the initial pilot study and is not the preferred administration method for ongoing treatment.

Storage and Handling#

The clinical trial formulation was provided as a sterile aqueous solution ready for injection. For research-grade material, lyophilized ARA-290 should be stored at -20 degrees Celsius. Reconstituted solutions should be stored at 2-8 degrees Celsius and used within a reasonable timeframe. Standard peptide handling precautions apply, including avoidance of repeated freeze-thaw cycles and protection from light.

Treatment Duration#

Clinical trials have evaluated ARA-290 over 28-day treatment periods. The optimal treatment duration for different conditions has not been established. Given that nerve fiber regeneration is a gradual process, longer treatment periods may be necessary for maximal therapeutic benefit. The persistence of corneal nerve fiber density improvements at the 28-day post-treatment assessment in the diabetes study suggests that some benefits may be sustained after treatment cessation.

Dose-Response Data#

Formal dose-response studies with multiple dose levels have not been extensively published. The 2 mg IV and 4 mg SC doses used in clinical trials were selected based on preclinical data and early pharmacokinetic studies. Whether lower or higher doses might provide better efficacy or a different adverse effect profile remains to be determined in future clinical studies.

Related Reading#

• ARA-290 overview and research guide
• ARA-290 side effects profile
• ARA-290 research evidence